ANI Pharmaceuticals (NASDAQ:ANIP) Stock Gets Price Target Boost from Guggenheim

ANI Pharmaceuticals (NASDAQ:ANIP) had its price target boosted by Guggenheim from $119.00 to $121.00 in a note issued to investors on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. Guggenheim‘s price objective would suggest a potential upside of 76.08% from the stock’s current price.

A number of other research firms have also recently commented on ANIP. Wall Street Zen cut ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Canaccord Genuity Group dropped their price objective on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a research note on Monday, August 10th. Leerink Partners initiated coverage on ANI Pharmaceuticals in a research note on Wednesday, September 9th. They issued an “outperform” rating and a $104.00 price objective for the company. Oppenheimer assumed coverage on ANI Pharmaceuticals in a report on Wednesday, September 23rd. They issued a “market perform” rating and a $85.00 price objective on the stock. Finally, Weiss Ratings lowered ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, August 11th. Three equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $100.00.

ANI Pharmaceuticals Trading Down 1.3%

Shares of ANI Pharmaceuticals stock traded down $0.90 on Friday, reaching $68.72. The company had a trading volume of 113,309 shares, compared to its average volume of 381,472. The firm’s 50 day moving average price is $72.65 and its two-hundred day moving average price is $77.41. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.41 and a current ratio of 2.91. ANI Pharmaceuticals has a 52-week low of $68.79 and a 52-week high of $95.45. The firm has a market cap of $1.58 billion, a PE ratio of 14.85, a PEG ratio of 2.31 and a beta of 0.45.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Thursday, November 5th. The specialty pharmaceutical company reported $2.70 earnings per share for the quarter, topping analysts’ consensus estimates of $2.18 by $0.52. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The firm had revenue of $290.78 million during the quarter, compared to analysts’ expectations of $280.59 million. During the same quarter last year, the company posted $2.04 EPS. The firm’s quarterly revenue was up 27.6% on a year-over-year basis. Sell-side analysts predict that ANI Pharmaceuticals will post 7.76 earnings per share for the current fiscal year.

Insider Activity

In other ANI Pharmaceuticals news, CEO Nikhil Lalwani sold 5,400 shares of the company’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $71.89, for a total transaction of $388,206.00. Following the sale, the chief executive officer owned 333,689 shares in the company, valued at $23,988,902.21. This represents a 1.59% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Meredith Cook sold 500 shares of the stock in a transaction dated Tuesday, October 13th. The shares were sold at an average price of $73.59, for a total value of $36,795.00. Following the completion of the sale, the vice president directly owned 73,424 shares in the company, valued at $5,403,272.16. This represents a 0.68% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 30,412 shares of company stock worth $2,220,970 over the last three months. Company insiders own 8.10% of the company’s stock.

Institutional Trading of ANI Pharmaceuticals

Large investors have recently made changes to their positions in the company. Bank of America Corp DE acquired a new stake in ANI Pharmaceuticals in the second quarter valued at approximately $15,154,000. NFJ Investment Group LLC acquired a new position in ANI Pharmaceuticals during the 2nd quarter worth approximately $2,766,000. Walleye Capital LLC acquired a new position in ANI Pharmaceuticals during the 2nd quarter worth approximately $8,784,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in ANI Pharmaceuticals during the 2nd quarter worth approximately $1,449,000. Finally, Jupiter Topco LLC acquired a new position in ANI Pharmaceuticals during the 2nd quarter worth approximately $6,597,000. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

Key ANI Pharmaceuticals News

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: Q3 results beat expectations: ANI reported adjusted earnings of $2.70 per share versus consensus of about $2.18, while revenue of $290.78 million exceeded estimates of $280.59 million. Revenue increased 27.6% year over year, and EPS rose from $2.04. The earnings beat and growth are supportive of the stock. ANI Pharmaceuticals Q3 2026 results
• Positive Sentiment: Proposed Egetis acquisition would expand rare-disease business: ANI made a recommended public offer valued at approximately SEK 5.6 billion (about $560 million) for Swedish biotech Egetis Therapeutics. The deal could broaden ANI’s rare-disease portfolio and growth opportunities. ANI Pharmaceuticals Egetis offer
• Neutral Sentiment: Acquisition adds execution and financial considerations: The offer’s strategic rationale is clear, but investors will weigh its cost, funding implications and integration alongside the potential benefits. ANI offer to acquire Egetis
• Negative Sentiment: Shares remain near their one-year low: That weak trading context indicates investor caution persists despite the earnings beat; the acquisition’s cost and execution may be among the issues investors are considering.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with limited competition, complex formulations and specialized manufacturing requirements, serving therapeutic areas that include endocrinology, immunology, ophthalmology, dermatology and central nervous system disorders.

ANI’s portfolio includes branded products and generic medicines, as well as treatments for rare diseases.